Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists

Latest MPM ONCOLOGY IMPACT MANAGEMENT LP Stock Portfolio

$621Million– No. of Holdings #37

MPM ONCOLOGY IMPACT MANAGEMENT LP Performance:
2024 Q1: 21.16%YTD: 21.16%2023: -3.88%

Performance for 2024 Q1 is 21.16%, and YTD is 21.16%, and 2023 is -3.88%.

About MPM ONCOLOGY IMPACT MANAGEMENT LP and 13F Hedge Fund Stock Holdings

MPM BIOIMPACT LLC is a hedge fund based in CHESTNUT HILL, MA. On 29-Mar-2021, the fund reported that it had an AUM (Regulated Assets under Management) of $1.2 Billions. In it's latest 13F Holdings report, MPM BIOIMPACT LLC reported an equity portfolio of $622 Millions as of 31 Mar, 2024.

The top stock holdings of MPM BIOIMPACT LLC are CGEM, GERN, IOVA. The fund has invested 21% of it's portfolio in CULLINAN ONCOLOGY, INC. and 5.6% of portfolio in GERON CORPORATION.

The fund managers got completely rid off KARUNA THERAPEUTICS INC (KRTX), CYMABAY THERAPEUTICS INC (CBAY) and STRUCTURE THERAPEUTICS INC. stocks. They significantly reduced their stock positions in VIKING THERAPEUTICS INC (VKTX), IOVANCE BIOTHERAPEUTICS INC (IOVA) and GERON CORPORATION (GERN). MPM BIOIMPACT LLC opened new stock positions in ZENTALIS PHARMACEUTICALS, INC. (ZNTL), SUTRO BIOPHARMA, INC. (STRO) and NATERA INC (NTRA). The fund showed a lot of confidence in some stocks as they added substantially to VIRIDIAN THERAPEUTICS INC (VRDN), DISC MEDICINE INC and MADRIGAL PHARMACEUTICALS INC (MDGL).
MPM ONCOLOGY IMPACT MANAGEMENT LP Equity Portfolio Value
Last Reported on: 15 May, 2024

MPM ONCOLOGY IMPACT MANAGEMENT LP Annual Return Estimates Vs S&P 500

Our best estimate is that MPM BIOIMPACT LLC made a return of 21.16% in the last quarter. In trailing 12 months, it's portfolio return was 26.93%.

New Buys

Ticker$ Bought
zentalis pharmaceuticals, inc.23,895,000
sutro biopharma, inc.23,145,900
natera inc15,768,900
ultragenyx pharmaceutical inc11,466,600
89bio inc11,264,500
fulcrum therapeutics inc10,734,300
kalvista pharmaceuticals inc9,022,160
akero therapeutics inc8,409,660

New stocks bought by MPM ONCOLOGY IMPACT MANAGEMENT LP

Additions

Ticker% Inc.
viridian therapeutics inc514
disc medicine inc121
madrigal pharmaceuticals inc50.08
avadel pharmaceuticals plc31.00
axsome therapeutics, inc.22.21
intellia therapeutics, inc.13.07
xeris biopharma holdings inc8.3
olema pharmaceuticals, inc.5.2

Additions to existing portfolio by MPM ONCOLOGY IMPACT MANAGEMENT LP

Reductions

Ticker% Reduced
viking therapeutics inc-53.89
iovance biotherapeutics inc -33.12
geron corporation-2.24
revolution medicines, inc. -0.07

MPM ONCOLOGY IMPACT MANAGEMENT LP reduced stake in above stock

Sold off

Ticker$ Sold
cymabay therapeutics inc-14,436,100
inozyme pharma inc.-1,379,440
harpoon therapeutics, inc.-3,634,650
structure therapeutics inc.-9,403,170
phathom pharmaceuticals inc-639,100
karuna therapeutics inc-16,863,300

MPM ONCOLOGY IMPACT MANAGEMENT LP got rid off the above stocks

Sector Distribution

MPM BIOIMPACT LLC has about 98.9% of it's holdings in Healthcare sector.

Sector%
Healthcare98.9
Others1.1

Market Cap. Distribution

MPM BIOIMPACT LLC has about 2.6% of it's portfolio invested in the large-cap and mega-cap stocks.

Category%
SMALL-CAP59.2
MID-CAP31.9
MICRO-CAP5.1
LARGE-CAP2.6
UNALLOCATED1.1

Stocks belong to which Index?

About 82.9% of the stocks held by MPM BIOIMPACT LLC either belong to S&P 500 or RUSSELL 2000 index.

Index%
RUSSELL 200082.9
Others17.1
Top 5 Winners (%)%
VKTX
viking therapeutics inc
208.0 %
ADAP
adaptimmune therapeutics plc
99.2 %
HOWL
werewolf therapeutics, inc.
67.9 %
CGEM
cullinan oncology, inc.
67.2 %
IOVA
iovance biotherapeutics inc
59.3 %
Top 5 Winners ($)$
CGEM
cullinan oncology, inc.
52.4 M
IOVA
iovance biotherapeutics inc
15.9 M
VKTX
viking therapeutics inc
12.6 M
GERN
geron corporation
12.4 M
HOWL
werewolf therapeutics, inc.
6.3 M
Top 5 Losers (%)%
RPTX
repare therapeutics, inc.
-35.5 %
ALXO
alx oncology holdings inc.
-25.1 %
RLAY
relay therapeutics inc.
-24.6 %
OLMA
olema pharmaceuticals, inc.
-18.9 %
FOLD
amicus therapeutics inc.
-16.9 %
Top 5 Losers ($)$
OLMA
olema pharmaceuticals, inc.
-5.1 M
ALXO
alx oncology holdings inc.
-4.7 M
RPTX
repare therapeutics, inc.
-4.2 M
MLTX
moonlake immunotherapeutics
-3.0 M
RLAY
relay therapeutics inc.
-2.3 M

MPM ONCOLOGY IMPACT MANAGEMENT LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of MPM ONCOLOGY IMPACT MANAGEMENT LP

MPM BIOIMPACT LLC has 37 stocks in it's portfolio. About 55.5% of the portfolio is in top 10 stocks. OLMA proved to be the most loss making stock for the portfolio. CGEM was the most profitable stock for MPM BIOIMPACT LLC last quarter.

Last Reported on: 15 May, 2024
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions